AVIR
NASDAQ HealthcareAtea Pharmaceuticals, Inc. - common stock
Biotechnology
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $5.22 |
|---|---|
| Volume | 224,487 |
| Market Cap | 418.67M |
| Beta | 0.270 |
| RSI (14-Day) | 61.5 |
| 200-Day MA | $4.44 |
| 50-Day MA | $4.69 |
| 52-Week High | $6.45 |
| 52-Week Low | $2.78 |
| Forward P/E | -3.53 |
| Price / Book | 2.05 |
๐ฏ Investment Strategy Scores
AVIR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (63/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Institutional Whale (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find AVIR in your text
Paste any article, transcript, or post โ the tool will extract AVIR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.